University Of Vermont Medical Center
- Type
- Teaching hospital
- Where
- Burlington, VT
- Medicare CCN
- 470003
- Received
- $3,628,142 in 556 records, 2022 ($105,933 general, $3,522,208 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: THE UNIVERSITY OF VERMONT MEDICAL CENTER, INC. Fuzzy (name and state)
- Federal award recipient: UNIVERSITY OF VERMONT MEDICAL CENTER INC., THE Fuzzy (name and state)
- Nonprofit: UNIVERSITY OF VERMONT MEDICAL CENTER INC Fuzzy (name and state)
- Trademark owner: The University of Vermont Medical Center Inc. Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | General payment | 33 | $105,933 |
| 2022 | Research payment | 523 | $3,522,208 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 523 | $3,522,208 |
| Long term medical supply or device loan | 6 | $64,253 |
| Grant | 4 | $37,700 |
| Space rental or facility fees (teaching hospital only) | 3 | $3,750 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 19 | $185 |
| Royalty or License | 1 | $45 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | Merck Sharp & Dohme LLC | $145,266 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $48,523 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2022 |
| 2022-12-31 | AngioDynamics, Inc. | $47,666 | Long term medical supply or device loan | In-kind items and services | NanoKnife Device, Oncology Surgery | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $27,220 | Research payment | In-kind items and services | TICE BCG Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2022 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $20,356 | Research payment | In-kind items and services | A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and | 2022 | |
| 2022-12-31 | AngioDynamics, Inc. | $16,333 | Long term medical supply or device loan | In-kind items and services | Auryon Laser System 100-120 Vac Device, ET | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $14,118 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $12,681 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2022 |
| 2022-12-31 | AstraZeneca UK Limited | $10,754 | Research payment | In-kind items and services | TAGRISSO Drug, Oncology | AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non small Cell Lung Cancer | 2022 |
| 2022-12-31 | Philips North America LLC | $6,000 | Research payment | In-kind items and services | (6260) Ingenia 3 0T R5 Device, Medical Device | WF-010536 / Evaluation of Image Quality of 3D Synthetic MRI in Children | 2022 |
| 2022-12-31 | Philips North America LLC | $6,000 | Research payment | In-kind items and services | (6260) Ingenia 3 0T R5 Device, Medical Device | WF-010536 / Evaluation of Image Quality of 3D Synthetic MRI in Children | 2022 |
| 2022-12-31 | Philips North America LLC | $6,000 | Research payment | In-kind items and services | (6260) Ingenia 3 0T R5 Device, Medical Device | WF-010536 / Evaluation of Image Quality of 3D Synthetic MRI in Children | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,125 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $3,878 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $3,807 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2,369 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemothera | 2022 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $2,261 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,107 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemothera | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $613 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $416 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2022 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $334 | Research payment | In-kind items and services | BREZTRI Drug, Respiratory | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Effi | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $136 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2022 |
| 2022-12-28 | Alexion Pharmaceuticals, Inc. | $580 | Research payment | Cash or cash equivalent | Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Compl | 2022 | |
| 2022-12-25 | Novocure GmbH | $5,453 | Research payment | Cash or cash equivalent | EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiat | 2022 | |
| 2022-12-23 | Roche Products Limited | $3,954 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OBSERVATIONAL STUDY OF OCRELIZUMAB TREATED MULTIPLE SCLEROSIS PATIENTS US COMMITMENT | 2022 |
| 2022-12-22 | AstraZeneca UK Limited | $75,624 | Research payment | Cash or cash equivalent | TAGRISSO Drug, Oncology | AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non small Cell Lung Cancer | 2022 |
| 2022-12-22 | Procept Biorobotics Corporation | $2,500 | Research payment | Cash or cash equivalent | AQUABEAM ROBOTIC SYSTEM Device, Urology | WATER II | 2022 |
| 2022-12-21 | Merck Sharp & Dohme LLC | $57,082 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2022 |
| 2022-12-21 | Novo Nordisk AS | $1,876 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2022 |
| 2022-12-21 | Novo Nordisk AS | $1,608 | Research payment | Cash or cash equivalent | Rybelsus Drug, Diabetes | EX9924-4473 | 2022 |
| 2022-12-21 | Agios Pharmaceuticals, Inc. | $1,500 | Research payment | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | PyruvateKinase Deficiency Global Longitudinal Registry | 2022 |
| 2022-12-21 | Novo Nordisk AS | $415 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-21 | Neurocrine BioSciences, Inc. | $156 | Research payment | Cash or cash equivalent | OPEN-LABEL ROLLOVER STUDY FOR CONTINUING VALBENAZINE ADMINISTRATION FOR THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGT | 2022 | |
| 2022-12-21 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-19 | Genentech, Inc. | $49,523 | Research payment | Cash or cash equivalent | Drug | A PHASE 2B EFFICACY SAFETY TRIAL OF PRASINEZUMAB IN PATIENTS WITH EARLY PARKINSON S DISEASE | 2022 |
| 2022-12-19 | Boston Scientific Corporation | $8,711 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-12-19 | Boston Scientific Corporation | $1,628 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-12-19 | Neurocrine BioSciences, Inc. | $1,500 | Research payment | Cash or cash equivalent | OPEN-LABEL ROLLOVER STUDY FOR CONTINUING VALBENAZINE ADMINISTRATION FOR THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGT | 2022 | |
| 2022-12-19 | Neurocrine BioSciences, Inc. | $200 | Research payment | Cash or cash equivalent | OPEN-LABEL ROLLOVER STUDY FOR CONTINUING VALBENAZINE ADMINISTRATION FOR THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGT | 2022 | |
| 2022-12-16 | EMD Serono, Inc. | $15,189 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2022 | |
| 2022-12-16 | F. Hoffmann-La Roche AG | $9,709 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | ROLL OVER PROTOCOL FOR 3 OCR PIVOTAL STUDIES OPERA I OPERA II AND ORATORIO TO EXTEND THE OLE | 2022 |
| 2022-12-16 | ABBVIE INC. | $131 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | A Long-Term Registry of Humira?? (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) | 2022 |
| 2022-12-15 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $16 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $16 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $16 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $16 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $16 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $16 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $16 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $16 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $16 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $16 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $16 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $16 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $16 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $16 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-14 | Intercept Pharmaceuticals, Inc. | $2,549 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-12-12 | SANOFI US SERVICES INC. | $18,135 | Research payment | Cash or cash equivalent | An Open Label Randomized Phase 2 Trial of SAR439859, Versus Endocrine Monotherapy as Per Physician's Choice in Premenopa | 2022 | |
| 2022-12-12 | GENZYME CORPORATION | $8,680 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonre | 2022 | |
| 2022-12-11 | Novocure GmbH | $2,500 | Research payment | Cash or cash equivalent | EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiat | 2022 | |
| 2022-12-09 | Horizon Therapeutics plc | $4,328 | Research payment | Cash or cash equivalent | UPLIZNA Drug, UPLIZNA | A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 3 STUDY WITH OPEN-LABEL PERIOD TO EVALUATE THE EFFICAC | 2022 |
| 2022-12-08 | Medtronic, Inc. | $28,021 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | PSR-CVG | 2022 |
| 2022-12-08 | Medtronic, Inc. | $8,115 | Research payment | Cash or cash equivalent | VIVA XT CRT-D Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2022 |
| 2022-12-08 | Medtronic, Inc. | $666 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | PSR-CVG | 2022 |
| 2022-12-08 | Medtronic, Inc. | $546 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | PSR-CVG | 2022 |
| 2022-12-02 | Regeneron Pharmaceuticals, Inc. | $4,941 | Research payment | Cash or cash equivalent | A Multicenter, Phase 2, Open-label Study of Intratumoral CMP-001 in Combination With Intravenous Pembrolizumab in Subjec | 2022 | |
| 2022-12-02 | Novo Nordisk AS | $962 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2022 |
| 2022-12-01 | ABBVIE INC. | $8,201 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | Study Comparing Intravenous (IV)x2FSubcutaneous (SC) Risankizumab to IVx2FSC Ustekinumab to Assess Change in Crohnx27s D | 2022 |
| 2022-12-01 | EMD Serono, Inc. | $650 | Research payment | Cash or cash equivalent | Mavenclad Drug, Neurology | Observational evaluation of effectiveness and patient-reported outcomeS (PROs) in suboPtimally controlled patients previ | 2022 |
| 2022-12-01 | ABBVIE INC. | $438 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | A Long-Term Registry of Humira?? (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) | 2022 |
| 2022-11-30 | Novo Nordisk AS | $941 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-11-28 | Genentech, Inc. | $3,795 | Research payment | Cash or cash equivalent | VABYSMO Drug, Immunology and Ophthalmology | FARICIMAB DME LONG TERM EXTENSION RHONE X | 2022 |
| 2022-11-24 | EMD Serono, Inc. | $650 | Research payment | Cash or cash equivalent | Mavenclad Drug, Neurology | Observational evaluation of effectiveness and patient-reported outcomeS (PROs) in suboPtimally controlled patients previ | 2022 |
| 2022-11-23 | Roche TCRC, Inc. | $24,980 | Research payment | Cash or cash equivalent | Drug | PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS | 2022 |
| 2022-11-23 | Roche TCRC, Inc. | $5,716 | Research payment | Cash or cash equivalent | Drug | PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS | 2022 |
| 2022-11-23 | E.R. Squibb & Sons, L.L.C. | $2,695 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Stage III Unresectable NSCLC Combo - A Phase 3, Randomized, Open-Label Study to Compare Nivolumab Plus Concurr | 2022 |
| 2022-11-23 | Novo Nordisk AS | $1,500 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2022 |
| 2022-11-23 | Novo Nordisk AS | $585 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2022 |
| 2022-11-22 | Janssen Research & Development, LLC | $17,804 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Co | 2022 | |
| 2022-11-22 | Janssen Research & Development, LLC | $17,804 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Co | 2022 | |
| 2022-11-22 | EMD Serono, Inc. | $1,001 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) | 2022 |
| 2022-11-22 | EMD Serono, Inc. | $800 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) | 2022 |
| 2022-11-22 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Rybelsus Drug, Diabetes | EX9924-4473 | 2022 |
| 2022-11-16 | VERTEX PHARMACEUTICALS INCORPORATED | $3,500 | Research payment | Cash or cash equivalent | A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With | 2022 | |
| 2022-11-15 | F. Hoffmann-La Roche AG | $15,184 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OCRELIZUMAB IN PATIENTS WITH RMS | 2022 |
| 2022-11-14 | United Therapeutics Corporation | $1,500 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2022 | |
| 2022-11-11 | Medtronic, Inc. | $2,476 | Research payment | Cash or cash equivalent | VIVA XT CRT-D Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2022 |
| 2022-11-10 | Regeneron Pharmaceuticals, Inc. | $1,350 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY | 2022 |
| 2022-11-10 | Medtronic, Inc. | $450 | Research payment | In-kind items and services | Investigator Sponsored Research | 2022 | |
| 2022-11-09 | Medtronic, Inc. | $36,000 | Research payment | In-kind items and services | AZURE XT DR MRI SURESCAN Device, Pacemakers | Investigator Sponsored Research | 2022 |
| 2022-11-09 | ABBVIE INC. | $9,290 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | Study Comparing Intravenous (IV)x2FSubcutaneous (SC) Risankizumab to IVx2FSC Ustekinumab to Assess Change in Crohnx27s D | 2022 |
| 2022-11-09 | Intercept Pharmaceuticals, Inc. | $4,528 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-11-09 | Abbott Laboratories | $936 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, Structural Heart | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2022 |
| 2022-11-07 | Boston Scientific Corporation | $3,840 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-11-07 | Biogen, Inc. | $3,500 | Research payment | Cash or cash equivalent | A Phase 1 Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmac | 2022 | |
| 2022-11-03 | Regeneron Pharmaceuticals, Inc. | $2,746 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY | 2022 |
| 2022-11-03 | EMD Serono, Inc. | $2,383 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2022 | |
| 2022-11-03 | Abbott Laboratories | $1,500 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, Structural Heart | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2022 |
| 2022-11-03 | EMD Serono, Inc. | $692 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2022 | |
| 2022-11-02 | Roche TCRC, Inc. | $48,555 | Research payment | Cash or cash equivalent | Drug | PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS | 2022 |
| 2022-11-02 | GENZYME CORPORATION | $2,768 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonre | 2022 | |
| 2022-11-02 | EMD Serono, Inc. | $2,500 | Research payment | Cash or cash equivalent | Mavenclad Drug, Neurology | Observational evaluation of effectiveness and patient-reported outcomeS (PROs) in suboPtimally controlled patients previ | 2022 |
| 2022-11-02 | ABBVIE INC. | $1,854 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | Study Comparing Intravenous (IV)x2FSubcutaneous (SC) Risankizumab to IVx2FSC Ustekinumab to Assess Change in Crohnx27s D | 2022 |
| 2022-10-27 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $129 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PRIMARY CARE | Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Ri | 2022 |
| 2022-10-26 | F. Hoffmann-La Roche AG | $3,500 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | ROLL OVER PROTOCOL FOR 3 OCR PIVOTAL STUDIES OPERA I OPERA II AND ORATORIO TO EXTEND THE OLE | 2022 |
| 2022-10-24 | GENZYME CORPORATION | $12,412 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonre | 2022 | |
| 2022-10-21 | Novo Nordisk AS | $585 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2022 |
| 2022-10-21 | Novo Nordisk AS | $526 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-10-19 | Intercept Pharmaceuticals, Inc. | $7,822 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-10-17 | Boston Scientific Corporation | $22,680 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-10-17 | American Regent | $1,558 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Iron Deficiency Anemia | Heart_FID | 2022 |
| 2022-10-17 | Boston Scientific Corporation | $725 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-10-13 | Medtronic, Inc. | $5,565 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2022 |
| 2022-10-13 | Medtronic, Inc. | $5,565 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2022 |
| 2022-10-13 | Medtronic, Inc. | $2,069 | Research payment | Cash or cash equivalent | VIVA XT CRT-D Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2022 |
| 2022-10-11 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Rybelsus Drug, Diabetes | EX9924-4473 | 2022 |
| 2022-10-10 | Eli Lilly and Company | $205 | Research payment | In-kind items and services | POSTMONARCH: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS F | 2022 | |
| 2022-10-07 | Regeneron Pharmaceuticals, Inc. | $2,500 | Research payment | Cash or cash equivalent | A Multicenter, Phase 2, Open-label Study of Intratumoral CMP-001 in Combination With Intravenous Pembrolizumab in Subjec | 2022 | |
| 2022-10-07 | Roche Products Limited | $2,500 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OBSERVATIONAL STUDY OF OCRELIZUMAB TREATED MULTIPLE SCLEROSIS PATIENTS US COMMITMENT | 2022 |
| 2022-10-06 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-09-30 | Neurocrine BioSciences, Inc. | $3,524 | Research payment | Cash or cash equivalent | OPEN-LABEL ROLLOVER STUDY FOR CONTINUING VALBENAZINE ADMINISTRATION FOR THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGT | 2022 | |
| 2022-09-30 | Novo Nordisk AS | $1,831 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2022 |
| 2022-09-28 | Novo Nordisk AS | $325 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-09-23 | ARGENX US, INC. | $2,500 | Research payment | Cash or cash equivalent | A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chr | 2022 | |
| 2022-09-23 | Roche Products Limited | $912 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OBSERVATIONAL STUDY OF OCRELIZUMAB TREATED MULTIPLE SCLEROSIS PATIENTS US COMMITMENT | 2022 |
| 2022-09-22 | ABBVIE INC. | $1,305 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | A Long-Term Registry of Humira?? (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) | 2022 |
| 2022-09-21 | Amryt Pharma Holdings Ltd | $227 | Research payment | Cash or cash equivalent | Juxtapid Drug, Cardiology/Vascular Diseases | LOWER: Lomitapide Observational Worldwide Evaluation Registry | 2022 |
| 2022-09-20 | Genentech, Inc. | $37,610 | Research payment | Cash or cash equivalent | Drug | A PHASE 2B EFFICACY SAFETY TRIAL OF PRASINEZUMAB IN PATIENTS WITH EARLY PARKINSON S DISEASE | 2022 |
| 2022-09-20 | Boston Scientific Corporation | $16,444 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-09-20 | Boston Scientific Corporation | $644 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-09-19 | EMD Serono, Inc. | $1,001 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) | 2022 |
| 2022-09-19 | EMD Serono, Inc. | $1,001 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) | 2022 |
| 2022-09-19 | EMD Serono, Inc. | $764 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) | 2022 |
| 2022-09-19 | EMD Serono, Inc. | $764 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) | 2022 |
| 2022-09-19 | EMD Serono, Inc. | $764 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) | 2022 |
| 2022-09-19 | EMD Serono, Inc. | $656 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) | 2022 |
| 2022-09-16 | United Therapeutics Corporation | $396 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2022 | |
| 2022-09-16 | United Therapeutics Corporation | $195 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2022 | |
| 2022-09-15 | Endologix LLC | $553 | Research payment | Cash or cash equivalent | AFX2 Bifurcated Endograft System Device, Cardiology/Vascular Diseases | LEOPARD | 2022 |
| 2022-09-14 | Roche TCRC, Inc. | $20,286 | Research payment | Cash or cash equivalent | Drug | PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS | 2022 |
| 2022-09-14 | AstraZeneca Pharmaceuticals LP | $7,375 | Research payment | Cash or cash equivalent | BREZTRI Drug, Respiratory | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Effi | 2022 |
| 2022-09-14 | Roche TCRC, Inc. | $2,752 | Research payment | Cash or cash equivalent | Drug | PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS | 2022 |
| 2022-09-14 | Roche TCRC, Inc. | $1,241 | Research payment | Cash or cash equivalent | Drug | PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS | 2022 |
| 2022-09-14 | Roche TCRC, Inc. | $1,140 | Research payment | Cash or cash equivalent | Drug | PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS | 2022 |
| 2022-09-14 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor ( | 2022 | |
| 2022-09-13 | F. Hoffmann-La Roche AG | $9,012 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OCRELIZUMAB IN PATIENTS WITH RMS | 2022 |
| 2022-09-08 | Medtronic, Inc. | $29,493 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | PSR-CVG | 2022 |
| 2022-09-08 | ABBVIE INC. | $1,935 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | Study Comparing Intravenous (IV)x2FSubcutaneous (SC) Risankizumab to IVx2FSC Ustekinumab to Assess Change in Crohnx27s D | 2022 |
| 2022-09-08 | Medtronic, Inc. | $1,876 | Research payment | Cash or cash equivalent | VIVA XT CRT-D Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2022 |
| 2022-09-08 | EMD Serono, Inc. | $1,102 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2022 | |
| 2022-09-08 | EMD Serono, Inc. | $1,019 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2022 | |
| 2022-09-08 | EMD Serono, Inc. | $768 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2022 | |
| 2022-09-08 | EMD Serono, Inc. | $500 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2022 | |
| 2022-09-08 | EMD Serono, Inc. | $486 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2022 | |
| 2022-09-08 | Medtronic, Inc. | $405 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | PSR-CVG | 2022 |
| 2022-09-08 | Medtronic, Inc. | $11 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | PSR-CVG | 2022 |
| 2022-09-07 | Roche TCRC, Inc. | $46,189 | Research payment | Cash or cash equivalent | Drug | PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS | 2022 |
| 2022-09-07 | Zimmer Biomet Holdings, Inc. | $1,000 | Research payment | Cash or cash equivalent | Comprehensive Shoulder System Device, Extremities | MDR Comprehensive Primary Micro Stem Titanium Versa-Dial Humeral Head | 2022 |
| 2022-09-06 | Medtronic, Inc. | $1,500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve EUS | 2022 |
| 2022-09-06 | F. Hoffmann-La Roche AG | $904 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OCRELIZUMAB IN PATIENTS WITH RMS | 2022 |
| 2022-08-30 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $12,760 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PRIMARY CARE | Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of R | 2022 |
| 2022-08-29 | Sage Therapeutics, LLC | $3,500 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE EFFECTS OF SAGE-718 IN PARTICIPANTS WITH PARKINSON'S DISEASE COGNITIVE IMPAIRMENT | 2022 | |
| 2022-08-26 | Genentech, Inc. | $2,426 | Research payment | Cash or cash equivalent | VABYSMO Drug, Immunology and Ophthalmology | FARICIMAB DME LONG TERM EXTENSION RHONE X | 2022 |
| 2022-08-26 | Novo Nordisk AS | $270 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2022 |
| 2022-08-26 | Novo Nordisk AS | $195 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2022 |
| 2022-08-25 | EMD Serono, Inc. | $1,086 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-08-24 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
The latest 200 records of 556.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Burlington, VT, county Chittenden County, VT, state Vermont; placed by its city name.
| Measure | Place (city or town) Burlington, VT | County Chittenden County, VT | State Vermont |
|---|---|---|---|
| Population B01003 | 44,675 | 169,758 | 647,106 |
| Population, 2020 census P1 | 44,743 | 168,323 | 643,077 |
| Median age B01002 | 26.8 | 37.3 | 43.1 |
| Under 18 B01001 | 11.1% | 17.2% | 17.9% |
| 65 and over B01001 | 12.1% | 16.9% | 21.4% |
| Households B11001 | 17,504 | 71,456 | 273,416 |
| Foreign born B05002 | 7.1% | 7.9% | 4.3% |
| Median household income B19013 | $71,109 | $96,759 | $81,203 |
| Median family income B19113 | $130,243 | $131,883 | $105,211 |
| Per capita income B19301 | $40,192 | $52,322 | $46,500 |
| Poverty rate B17001 | 20.5% | 9.7% | 10.1% |
| Unemployment rate B23025 | 4.3% | 3.2% | 3.6% |
| Civilian labor force B23025 | 26,390 | 101,136 | 352,132 |
| Mean commute (minutes) B08013 | 18.7 | 21.1 | 23.5 |
| Bachelor's degree or higher B15003 | 60.5% | 56.8% | 43.8% |
| Housing units B25001 | 18,079 | 74,888 | 339,042 |
| Owner-occupied B25003 | 41.5% | 63.9% | 73.2% |
| Renters B25003 | 58.5% | 36.1% | 26.8% |
| Median home value B25077 | $444,800 | $439,200 | $316,600 |
| Median gross rent B25064 | $1,649 | $1,646 | $1,234 |
| White, not Hispanic B03002 | 84.1% | 85.5% | 89.9% |
| Black B03002 | 2.9% | 2.3% | 1.1% |
| Hispanic or Latino B03002 | 2.8% | 2.9% | 2.6% |
| Asian B03002 | 4.2% | 4.4% | 1.8% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Burlington, VT.
Comments